Fertility lab tests and preconception blood tests can answer focused questions about ovulation, ovarian reserve, reproductive hormones, thyroid function, metabolic health, infection risk, immunity, blood type, and selected inherited conditions. They cannot determine fertility by themselves, guarantee pregnancy, measure egg quality directly, show whether the fallopian tubes are open, diagnose every pelvic condition, or replace semen analysis and a clinical evaluation.
The best starting point is not the largest panel. It is a clear question, the right person or people tested, correct cycle timing when timing matters, and a plan for interpreting abnormal or conflicting results. For broader background, see the complete guide to lab tests and blood work.
Important: This page is educational and does not diagnose infertility or replace care from an obstetrician-gynecologist, reproductive endocrinologist, urologist, genetic counselor, or other qualified clinician. A fertility evaluation often requires medical and reproductive history, physical examination, semen analysis, and imaging or procedures in addition to blood tests. Seek urgent care for severe or sudden pelvic or abdominal pain, fainting, shoulder pain, heavy bleeding, or a positive pregnancy test with concerning symptoms.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Ovulation assessment | Cycle history is often the first clue. A correctly timed progesterone measurement can provide evidence of recent ovulation when the history is unclear. | Timing is based on the expected next period, not a universal calendar day. One value cannot grade the quality of the luteal phase. |
| Ovarian reserve assessment | AMH, early-follicular FSH with estradiol, and antral follicle count may help estimate ovarian response to stimulation. | These tests estimate egg quantity or ovarian response, not egg quality or the chance of natural conception by themselves. Age and the full clinical picture remain central. |
| Male fertility assessment | Semen analysis is a core initial test. Targeted hormone testing may help when symptoms, examination, or semen findings suggest an endocrine cause. | Blood hormone results do not measure sperm count, movement, shape, or semen volume and do not replace semen analysis. |
| Preconception health assessment | Selected tests may review blood count, blood type, red-cell antibodies, glucose status, immunity, infections, nutrient status, and inherited-condition carrier risk. | Selection depends on health history, medicines, vaccination records, ancestry, exposures, prior pregnancy history, and the clinician's plan. Not every person needs every test. |
| Pregnancy testing | Human chorionic gonadotropin (hCG) testing answers whether pregnancy hormone is detected or measures its concentration. | Pregnancy testing is different from an infertility evaluation. A single hCG result cannot determine pregnancy location or always establish viability. |
Laboratory testing can support screening, diagnosis, risk assessment, baseline measurement, treatment planning, or monitoring. Its meaning changes with the reason for testing. For example, progesterone can be used to support evidence of recent ovulation, while serial hormone testing may be used in a treatment cycle under a specialist's direction.
| Question | What laboratory testing may contribute | What else may be needed |
|---|---|---|
| Is ovulation occurring? | Menstrual history, urine LH tracking, or a correctly timed serum progesterone result may contribute. | Clinical history and, when indicated, ultrasound or specialist monitoring. |
| How might the ovaries respond to stimulation? | AMH and early-follicular FSH with estradiol may add information. | Age, diagnosis, antral follicle count, prior response, and treatment goals. |
| Is there a male factor? | Targeted FSH, testosterone, LH, prolactin, and other tests may identify an endocrine clue in selected cases. | Semen analysis, reproductive and medical history, examination, and sometimes urologic or genetic evaluation. |
| Are there uterine, tubal, or pelvic factors? | Blood tests may identify related endocrine or infectious clues but do not show anatomy. | Pelvic examination, ultrasound, hysterosalpingography, sonohysterography, or other clinician-directed evaluation. |
| Am I ready for pregnancy? | Risk-based tests can identify conditions worth addressing before conception. | Medication and vaccine review, chronic-condition management, nutrition, family history, and preconception counseling. |
In the absence of a known concern, the American Society for Reproductive Medicine advises evaluation after 12 months of regular, unprotected intercourse when the person providing the eggs is younger than 35, after 6 months at age 35 or older, and more immediately when older than 40. Evaluation should begin sooner when there are irregular or absent periods, suspected endometriosis or uterine or tubal disease, known or suspected male-factor infertility, sexual dysfunction, prior gonadotoxic treatment, or another condition associated with reduced fertility.1
When sperm is part of the pregnancy plan, evaluation of both partners should usually begin at the same time. People using donor sperm, donor eggs, reciprocal in vitro fertilization, or fertility preservation also benefit from an evaluation tailored to the intended treatment rather than a one-size-fits-all panel.
Call emergency services or seek urgent care for severe or sudden one-sided pelvic or lower abdominal pain, fainting or feeling faint, shoulder pain, heavy bleeding, or rapidly worsening symptoms, especially with a positive pregnancy test. These symptoms can occur with internal bleeding from an ectopic pregnancy and should not be managed by ordering more outpatient lab tests.12
Test choice should follow the clinical question. A regular, predictable cycle may already provide useful evidence of ovulation; broad hormone screening is not automatically required. When testing is indicated, timing and context matter.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Progesterone Test | A luteal-phase result can provide evidence of recent ovulation when menstrual history is indeterminate. It may also be monitored in specialist-directed cycles. | Draw about one week before the expected next period rather than automatically on day 21. Levels fluctuate substantially over hours, so one result cannot assess luteal-phase quality.1 |
| Luteinizing Hormone (LH) Test | May help evaluate ovulatory or pituitary-gonadal disorders. Urine LH kits detect the surge that often precedes ovulation, while a serum LH value answers a different question. | A single serum value does not prove that ovulation occurred. Baseline LH can be elevated in PMOS, and fertility medicines can change results. |
| Follicle-Stimulating Hormone (FSH) Test | Used with estradiol and clinical context to evaluate ovarian function, amenorrhea, or possible diminished ovarian reserve. | For ovarian-reserve assessment, basal FSH is generally measured with estradiol in the early follicular phase, usually cycle days 2 through 4. Results vary between cycles. |
| Estradiol Test | Helps interpret early-follicular FSH and may be used in cycle monitoring or evaluation of amenorrhea. | Interpret with cycle day, medicines, symptoms, and FSH. Estradiol alone is not an ovarian-reserve screening test. |
| Ovarian Reserve Assessment Marker AMH Test | Estimates the remaining follicle pool and can help predict ovarian response or egg yield during stimulation. | Can generally be measured on any cycle day. Hormonal contraception may lower AMH. AMH does not directly measure egg quality and is a poor independent predictor of natural conception or live birth. |
| Prolactin Test | Targeted evaluation for galactorrhea, absent or infrequent periods, or suspected hyperprolactinemia. | Stress, sleep, exercise, breast stimulation, pregnancy, and some medicines can raise prolactin. A mild elevation may need a careful repeat rather than an immediate diagnosis. |
| Prolactin, Total and Monomeric Test | May help evaluate a persistent elevated prolactin result and the possible contribution of macroprolactin. | This is a follow-up test, not routine fertility screening. A clinician should decide when it is appropriate. |
| Testosterone Free and Total Test | May support evaluation of biochemical androgen excess when symptoms such as hirsutism, acne, or irregular ovulation are present. | Interpret with symptoms, SHBG, medicines, assay method, and other causes of androgen excess. It does not diagnose PMOS by itself. |
| Sex Hormone-Binding Globulin (SHBG) Test | Adds context to total and free testosterone assessment. | Estrogen exposure, thyroid status, liver conditions, body composition, and medicines can change SHBG. |
| DHEA-S Test | May help evaluate an adrenal contribution to androgen excess. | Not a routine test for everyone trying to conceive. Interpret with symptoms and other androgen results. |
| 17-Hydroxyprogesterone Test | May be used when clinical signs suggest nonclassic congenital adrenal hyperplasia as a cause of androgen excess or ovulatory dysfunction. | Timing and follow-up depend on the clinical question. An abnormal screening result may require specialist-directed confirmation. |
| TSH Test | Helps identify thyroid dysfunction that may affect cycles, ovulation, pregnancy planning, and general health. | An abnormal result may require Free T4 and sometimes antibody testing. Pregnancy-specific targets and treatment decisions belong with a clinician. |
| T4 Free Test | Measures unbound thyroxine and helps interpret an abnormal TSH or suspected thyroid disease. | Usually interpreted with TSH. Medicines, acute illness, pregnancy, binding-protein changes, and assay interference can affect results.78 |
| TSH and Free T4 Test | Provides the two common thyroid measurements together when both are appropriate. | Not every person needs both tests initially. Review thyroid symptoms, pregnancy plans, medicines, and previous results with a clinician. |
| hCG Total Qualitative Test | Reports whether hCG is detected and can answer a pregnancy-status question. | Testing too early can produce a false-negative result. A positive result does not establish location or viability. |
| hCG Total Quantitative Test | Measures hCG concentration and may be used serially by a clinician when early pregnancy needs assessment. | A single value is not a complete pregnancy evaluation. Symptoms, repeat values, and ultrasound may be needed. |
For a broader explanation of reproductive hormones, see women's hormone blood tests. For a deeper thyroid discussion, see thyroid blood tests.
Ovarian reserve refers mainly to the number of oocytes remaining, not their quality. AMH and antral follicle count are useful predictors of ovarian response and egg yield during stimulation. Basal FSH and estradiol can add information when measured together early in the cycle. However, ovarian-reserve markers are poor independent predictors of natural conception and should not be used as a pass-or-fail fertility score.2
Antral follicle count requires ultrasound and cannot be replaced by blood testing. Tubal patency and uterine anatomy also require imaging or procedures. This is why a normal hormone panel cannot rule out an anatomic cause of infertility.
A menstrual history is often enough to establish a likely ovulatory pattern when cycles are regular and predictable. If the history is unclear, serum progesterone is usually drawn about one week before the expected next menstrual period. For a 28-day cycle that may fall near day 21, but for shorter or longer cycles the correct date changes. A single progesterone result may support evidence of recent ovulation but cannot measure overall luteal-phase quality because progesterone fluctuates substantially.1
Urine LH kits identify a surge that generally precedes ovulation by one to two days, but false-positive and false-negative results occur. PMOS can cause persistently higher baseline LH in some people. Serum LH testing is not interchangeable with home urine surge testing, and neither replaces clinical evaluation when cycles are absent or irregular.
In May 2026, the American Society for Reproductive Medicine endorsed the name Polyendocrine Metabolic Ovarian Syndrome (PMOS) for the condition formerly called Polycystic Ovary Syndrome (PCOS). The updated name emphasizes that this is a complex endocrine and metabolic condition rather than simply ovarian cysts.9
No single blood test diagnoses PMOS. Evaluation combines cycle and symptom history, evidence of androgen excess, appropriate laboratory testing, and sometimes ovarian imaging while excluding other causes. Depending on the presentation, targeted tests may include pregnancy testing, TSH, prolactin, total and free testosterone, SHBG, DHEA-S, 17-hydroxyprogesterone, and metabolic risk assessment. A result should be interpreted as part of the diagnostic process, not as an isolated label.
Endometriosis can contribute to pelvic pain and infertility, but there is no routine blood panel that confirms or excludes it. CA-125 is not a general screening test for endometriosis or infertility. History, examination, ultrasound or other imaging, response to treatment, and sometimes surgery are used according to the clinical situation. Normal hormone or inflammation results do not rule out endometriosis.13
The AUA/ASRM male infertility guideline recommends one or more semen analyses during the initial male evaluation. Semen analysis assesses features such as sperm concentration, motility, morphology, and semen characteristics. Blood hormone tests do not measure those features and should not be presented as a substitute.3
Hormone testing is targeted when there is impaired libido, erectile dysfunction, azoospermia or low sperm concentration, small testes, or another sign of endocrine dysfunction. A reproductive urologist may recommend additional genetic or imaging evaluation based on history, examination, and semen findings.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Semen analysis | Core initial assessment of sperm and semen characteristics; abnormal results can guide further evaluation. | Collection instructions and abstinence interval matter. Results vary, so more than one sample may be needed. No exact public Ulta product page was confirmed for this service on the review date. |
| Total Testosterone, MS Test | Used with symptoms and semen findings to evaluate androgen status. | Usually collected in the morning and repeated when low before a diagnosis is made. Exogenous testosterone can suppress sperm production and should be disclosed to the clinician. |
| Testosterone Free and Total Test | May add information when total testosterone does not fit symptoms or when binding-protein changes are suspected. | Interpret with SHBG, timing, symptoms, medicines, and the laboratory method. |
| Testosterone Total and Free with SHBG Test | Combines related androgen measurements when a clinician wants binding context. | A broader hormone result still does not assess sperm directly or identify every cause of male infertility. |
| FSH Test | Can help distinguish impaired sperm production from some central endocrine causes when semen findings or examination indicate testing. | Not recommended as a universal first-line blood test without clinical or semen-analysis indications. |
| LH Test | May help interpret low testosterone and pituitary-testicular signaling. | Typically targeted after testosterone or other findings point to an endocrine question. |
| Prolactin Test | May be useful with low libido, hypogonadotropic findings, or suspected pituitary disease. | Transient elevation and medication effects are common. Follow-up depends on the degree and persistence of elevation. |
| Estradiol Test | Sometimes used in targeted evaluation or treatment monitoring. | Not a stand-alone male fertility test. Interpret with the full endocrine and semen picture. |
For broader testosterone, SHBG, and metabolic context, see men's health blood tests.
Preconception testing is not the same as infertility testing. Its purpose is to identify selected health issues that could affect the person planning pregnancy, a future pregnancy, or a baby. The right list depends on medical history, prior pregnancies, family history, medicines, immunization documentation, exposures, and current preventive-screening recommendations.
Start with a preconception visit when possible. Review chronic conditions, all prescription and nonprescription medicines, supplements, vaccines, substance exposure, nutrition, mental health, and family history. Laboratory testing supports that visit; it does not replace it. Once pregnancy is confirmed, use the dedicated guide to pregnancy blood tests and prenatal screening.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Complete Blood Count with Differential and Platelets | Reviews hemoglobin, red-cell indices, white cells, and platelets; may identify anemia or another finding that needs follow-up. | A CBC does not identify the cause of anemia by itself. Iron, B12, folate, inherited hemoglobin conditions, bleeding, and other causes require context. |
| Ferritin, Iron and Total Iron-Binding Capacity Panel | May help assess iron stores and iron availability when anemia, heavy menstrual bleeding, dietary risk, or prior deficiency is present. | Ferritin can rise with inflammation. Iron measures vary with timing, intake, and supplements. Interpret the pattern with a CBC and clinical history. |
| Ferritin Test | Measures an iron-storage marker and may be used when iron deficiency is suspected or monitored. | A normal or high result does not always exclude iron deficiency during inflammation. Do not start high-dose iron solely from one value without guidance. |
| Hemoglobin A1c and Glucose Panel | May help identify or monitor glucose dysregulation before pregnancy, particularly with risk factors or a known metabolic condition. | Fasting requirements depend on the ordered components. A1c can be misleading with altered red-cell turnover or some hemoglobin variants. |
| Hemoglobin A1c Test | Estimates average glycemia over the preceding months and may support diabetes screening or monitoring. | It is not a direct fertility test. Interpretation can change with anemia, recent blood loss, transfusion, kidney disease, or hemoglobin variants. |
| Insulin Test | Sometimes used in targeted metabolic evaluation when a clinician has a specific question. | Not a universal fertility or PMOS screening test. Fasting status, glucose, medicines, and the clinical context are essential. |
| ABO Group and Rh Type | Identifies blood group and Rh type, information used in pregnancy care and transfusion planning. | Blood type does not measure fertility. Prenatal care may include repeat or additional testing according to clinical standards. |
| Red Blood Cell Antibody Screen with Reflex Testing | Looks for red-cell antibodies that may matter during pregnancy or transfusion. | A positive result requires identification and clinician-directed follow-up. A preconception result does not replace prenatal testing. |
| Rubella Titer Test | May document serologic evidence of rubella immunity when vaccination records are unavailable or immunity needs confirmation. | Vaccination documentation may already establish immunity. MMR is a live vaccine and is not given during pregnancy; vaccination decisions belong with a clinician.4 |
| Varicella Immunity Screen | May provide laboratory evidence of immunity to varicella-zoster virus. | Commercial assays can miss vaccine-induced immunity and produce a false-negative result. Vaccination records and clinical history matter.5 |
| Hepatitis B Surface Antigen Test with Reflex to Confirmation | Detects current hepatitis B surface antigen and reflexes to confirmation when indicated. | This is an infection marker, not an immunity test. Hepatitis B screening is repeated during each pregnancy according to prenatal guidance. |
| Hepatitis C Antibody Test with Reflex to RNA Quantitative PCR | Screens for hepatitis C exposure and uses RNA testing to assess current infection when the antibody is reactive. | Antibody and RNA answer different questions. Positive or discordant results need clinical interpretation and linkage to care. |
| RPR Test with Reflex to Titer and Confirmatory Testing | Screens for syphilis and performs follow-up testing according to the reflex pathway. | Screening and confirmatory tests can be discordant. Treatment and repeat testing require clinician or public-health guidance. |
| Chlamydia and Gonorrhea Test | Uses nucleic acid amplification testing to detect two common sexually transmitted infections. | Who should be screened depends on age, anatomy, exposure site, pregnancy status, and risk. The specimen site must match the exposure question.6 |
| HIV screening | Recommended at least once for most adolescents and adults and during every pregnancy, with repeat testing based on risk and clinical guidance. | No exact current Ulta product page was confirmed for an HIV screening test on the review date, so no product link is provided here. Testing method and window period affect interpretation.10 |
| Hemoglobinopathy Evaluation | May identify a hemoglobin variant or pattern relevant to anemia, carrier status, or pregnancy planning. | Results can require CBC correlation, iron evaluation, molecular testing, partner testing, and genetic counseling. |
| Vitamin B12 Test | Targeted assessment for deficiency risk, macrocytosis, restrictive diet, malabsorption, or neurologic symptoms. | Serum B12 can be affected by supplements and does not always reflect tissue status. Follow-up markers may be needed. |
| Folate Serum Test | May evaluate suspected folate deficiency or macrocytosis in a targeted workup. | Serum folate reflects recent intake. Testing is not a substitute for following preconception folic-acid guidance. |
| Vitamin B12 and Folate Panel | Combines two nutrient measurements when the clinical question includes macrocytosis or deficiency risk. | Supplements and recent intake can affect results. The panel is targeted, not a universal fertility screen. |
| Vitamin D 25-Hydroxy Total Test | Assesses vitamin D status when risk factors, symptoms, prior deficiency, or monitoring justify testing. | It is not a direct measure of fertility. Supplement doses should be based on clinical context rather than fertility claims. |
CDC guidance recommends 400 micrograms of folic acid daily beginning at least one month before pregnancy for people who can become pregnant, unless a clinician recommends a different dose for a specific risk.11 A blood folate result does not replace that preventive recommendation.
Carrier screening estimates whether a person carries a gene variant associated with an inherited condition. It does not measure fertility, and a carrier result usually does not mean that the tested person has the condition. Testing before pregnancy can leave more time for partner testing, genetic counseling, and informed discussion of reproductive options.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Cystic Fibrosis Expanded Carrier Screen | Looks for selected CFTR variants associated with cystic fibrosis carrier status. | A negative result reduces but does not eliminate carrier risk. The residual risk depends on the variants assessed and the person's background. |
| Spinal Muscular Atrophy Carrier Screen | Assesses carrier status for spinal muscular atrophy using the method described on the current product page. | Some silent-carrier configurations or uncommon variants may not be detected. Genetic counseling helps explain residual risk and partner testing. |
| Hemoglobinopathy Evaluation | May identify hemoglobin patterns associated with sickle-cell disease or trait, thalassemia, or another variant. | Recent transfusion, iron deficiency, and some variants complicate interpretation. Molecular confirmation may be needed. |
Family history, ancestry, prior results, the laboratory method, and the reproductive plan all affect test selection. Expanded panels can create uncertain or incidental findings. A genetic counselor or knowledgeable clinician can explain detection limits, residual risk, partner testing, and what a positive result means before decisions are made.1
An individual test is often best when there is one focused question. A panel may be convenient when its exact components match a clinician's plan, but more tests do not automatically provide a better fertility assessment. Before ordering, open the current product page and compare every included component with what has already been tested.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Fertility Monitoring Panel for Women | A grouped option for selected reproductive hormone measurements. | Confirm the current components and match collection to cycle timing. A panel does not evaluate anatomy or replace a fertility specialist. |
| Fertility Monitoring Panel for Men | A grouped option for selected male hormone measurements. | It does not replace semen analysis. Confirm current components and use results with symptoms and clinical findings. |
| Pre-Pregnancy Panel | A grouped preconception option whose current contents should be reviewed against personal history and clinician recommendations. | It does not include every test every person may need and may include tests that are unnecessary for some people. Prenatal testing is still required after conception. |
| Fertility and Reproductive Health Essential Female Lab Panel | A bundled option for selected female reproductive-health measurements. | Review current components, cycle timing, overlap with prior testing, and what question each result will answer. |
| Fertility and Reproductive Health Essential Male Lab Panel | A bundled option for selected male reproductive-health measurements. | Hormones do not measure sperm. Avoid assuming a normal panel rules out male-factor infertility. |
If you are using direct access, review direct-access lab testing before collection. Direct access can improve convenience, but it does not turn a laboratory value into a diagnosis or replace urgent care.
Start with the reason for the test, the specimen date and time, cycle day when relevant, medicines, symptoms, and the laboratory's own reference interval. A result marked high or low is not automatically a diagnosis, and an unflagged value is not automatically reassuring when the test was mistimed or the wrong question was asked.
Biological variation, assay variation, collection conditions, and medicines can create discordant results. Confirm unexpected findings before making major decisions. Use how to read and understand lab results for a broader explanation of flags, reference intervals, units, and trends.
No laboratory test is perfect. Testing very early can make hCG falsely negative. A transient prolactin elevation can trigger unnecessary imaging if it is not confirmed appropriately. A varicella antibody assay can miss vaccine-induced immunity. A large panel can produce incidental abnormalities simply because many measurements were taken.
Over-testing can increase cost, anxiety, repeat blood draws, and specialist referrals without improving outcomes. The safest approach is to test when the result is reasonably likely to change counseling, treatment, timing, or follow-up.
| Test and quick facts | What it shows and how it is used | Preparation, influences, and limitations |
|---|---|---|
| Broad reproductive hormone panels for everyone | May be appropriate for a defined symptom, abnormal cycle, semen finding, or treatment plan. | Routine use can create uninterpretable cycle-timing problems and incidental findings. |
| Inhibin B Test | Has selected specialist uses. | ASRM does not recommend inhibin B as a routine ovarian-reserve test because it is not as useful as established approaches.1 |
| CA-125 | Has specific clinical uses, primarily in oncology and selected specialist contexts. | Not a routine screening test for infertility or endometriosis. Benign conditions can raise it, and a normal result does not exclude endometriosis. |
| CRP or ESR as fertility tests | General inflammation markers used for specific medical questions. | They do not diagnose the cause of infertility or rule out endometriosis. |
| Routine prolactin without an indication | Appropriate with galactorrhea, oligomenorrhea, amenorrhea, or selected male endocrine findings. | Not recommended as a universal infertility test; transient elevations can lead to unnecessary follow-up. |
| Repeated AMH to track natural fertility | AMH can support ovarian-response counseling in the right context. | Serial testing does not provide a countdown to infertility and should not drive major decisions by itself. |
| Advanced sperm-function or genetic tests without an indication | May be appropriate after abnormal semen analysis, recurrent loss, severe sperm abnormalities, or a specialist assessment. | Not substitutes for the standard initial male evaluation and can produce results with uncertain clinical actionability. |
Ulta Lab Tests provides direct links to individual tests and selected panels so readers can review current product details. Use those pages to confirm the exact test name, included components, specimen, preparation, and current availability before ordering. Product links on this page are educational navigation, not a recommendation that every reader order every test.
Bring results to the clinician managing fertility, preconception health, thyroid disease, metabolic conditions, or pregnancy. A complete fertility evaluation may still require semen analysis, pelvic ultrasound, tubal assessment, genetic counseling, or other care that blood testing cannot provide.
There is no single best test. The most useful next step depends on age, cycle history, how long pregnancy has been attempted, symptoms, prior pregnancies, whether sperm is part of the plan, and the treatment goal. A semen analysis may be the highest-value first test for male-factor assessment, while menstrual history may answer whether ovulation is likely in someone with regular cycles.
No. AMH can help estimate ovarian reserve and predict response or egg yield during stimulation, but it does not directly measure egg quality and is a poor stand-alone predictor of natural conception. A low result does not mean pregnancy is impossible, and a high result does not guarantee pregnancy.
Basal FSH and estradiol are commonly measured together in the early follicular phase, generally cycle days 2 through 4, when ovarian-reserve assessment is indicated. AMH can usually be measured on any cycle day. Follow the clinician's plan because treatment-cycle monitoring uses different schedules.
No. It is generally drawn about one week before the expected next period. Day 21 is only an approximation for some 28-day cycles. The date should move when the usual cycle is shorter or longer.
No. Hormone tests can identify selected endocrine clues but do not measure sperm concentration, movement, shape, or semen volume. Semen analysis remains a core initial test in male infertility evaluation.
It may be used to rule pregnancy in or out before evaluating absent periods or starting certain treatments, but pregnancy testing answers a different question from infertility testing. A single hCG value cannot always determine pregnancy location or viability.
Usually not by default. Choose the smallest set that answers the clinical question, uses correct timing, and has a clear interpretation plan. Larger panels increase the chance of incidental or discordant findings.
Most people who can become pregnant are advised to take 400 micrograms of folic acid daily beginning at least one month before pregnancy unless a clinician recommends a different dose. Routine blood testing is not required before following that preventive guidance.
Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.
Written by: John R. | Originally published: August 1, 2026 | Last updated: August 7, 2026
Medical note: This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
